Align Technology, Inc.

LSE:0HCK Stock Report

Market Cap: US$16.8b

Align Technology Valuation

Is 0HCK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HCK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$331.80
Fair Value
33.2% undervalued intrinsic discount
14
Number of Analysts

Below Fair Value: 0HCK ($221.69) is trading below our estimate of fair value ($331.8)

Significantly Below Fair Value: 0HCK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HCK?

Key metric: As 0HCK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0HCK. This is calculated by dividing 0HCK's market cap by their current earnings.
What is 0HCK's PE Ratio?
PE Ratio37x
EarningsUS$441.57m
Market CapUS$16.82b

Price to Earnings Ratio vs Peers

How does 0HCK's PE Ratio compare to its peers?

The above table shows the PE ratio for 0HCK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.6x
CTEC ConvaTec Group
41.1x18.6%UK£5.1b
AMS Advanced Medical Solutions Group
40.9x20.8%UK£455.3m
SN. Smith & Nephew
36.7x19.8%UK£9.0b
TSTL Tristel
27.6x17.5%UK£178.8m
0HCK Align Technology
37x17.1%US$16.8b

Price-To-Earnings vs Peers: 0HCK is expensive based on its Price-To-Earnings Ratio (37x) compared to the peer average (36.6x).

Price to Earnings Ratio vs Industry

How does 0HCK's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0HCK 37.0xIndustry Avg. 32.3xNo. of Companies7PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0HCK is expensive based on its Price-To-Earnings Ratio (37x) compared to the European Medical Equipment industry average (32.1x).

Price to Earnings Ratio vs Fair Ratio

What is 0HCK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HCK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37x
Fair PE Ratio43.8x

Price-To-Earnings vs Fair Ratio: 0HCK is good value based on its Price-To-Earnings Ratio (37x) compared to the estimated Fair Price-To-Earnings Ratio (43.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HCK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$221.69
US$263.09
+18.7%
10.7%US$300.00US$206.00n/a14
Jan ’26US$206.94
US$263.81
+27.5%
11.8%US$320.00US$206.00n/a14
Dec ’25US$232.77
US$261.24
+12.2%
12.1%US$320.00US$200.00n/a13
Nov ’25US$208.08
US$261.24
+25.5%
12.1%US$320.00US$200.00n/a13
Oct ’25US$247.42
US$287.01
+16.0%
14.1%US$350.00US$215.00n/a13
Sep ’25US$236.35
US$287.01
+21.4%
14.1%US$350.00US$215.00n/a13
Aug ’25US$228.66
US$299.69
+31.1%
13.6%US$353.99US$215.00n/a13
Jul ’25US$243.29
US$333.43
+37.0%
11.8%US$400.00US$250.00n/a14
Jun ’25US$253.95
US$341.64
+34.5%
11.7%US$400.00US$250.00n/a14
May ’25US$280.62
US$336.55
+19.9%
12.0%US$400.00US$250.00n/a15
Apr ’25US$328.12
US$310.15
-5.5%
13.4%US$355.00US$215.00n/a15
Mar ’25US$304.29
US$309.14
+1.6%
13.0%US$350.00US$215.00n/a15
Feb ’25US$277.81
US$308.36
+11.0%
13.3%US$344.00US$215.00US$221.6914
Jan ’25US$275.92
US$277.58
+0.6%
19.9%US$344.00US$180.00US$206.9414
Dec ’24US$223.40
US$278.36
+24.6%
19.7%US$378.00US$180.00US$232.7714
Nov ’24US$180.97
US$278.36
+53.8%
19.7%US$378.00US$180.00US$208.0814
Oct ’24US$309.19
US$393.31
+27.2%
11.7%US$450.00US$270.00US$247.4213
Sep ’24US$374.26
US$393.31
+5.1%
11.7%US$450.00US$270.00US$236.3513
Aug ’24US$379.14
US$385.25
+1.6%
11.2%US$440.00US$270.00US$228.6612
Jul ’24US$353.74
US$354.91
+0.3%
13.9%US$420.00US$225.00US$243.2911
Jun ’24US$294.76
US$354.91
+20.4%
13.9%US$420.00US$225.00US$253.9511
May ’24US$322.40
US$354.91
+10.1%
13.9%US$420.00US$225.00US$280.6211
Apr ’24US$327.81
US$334.27
+2.0%
16.7%US$420.00US$190.00US$328.1211
Mar ’24US$308.82
US$333.70
+8.1%
17.5%US$420.00US$190.00US$304.2910
Feb ’24US$273.07
US$241.00
-11.7%
20.5%US$314.00US$160.00US$277.8110
Analyst Price Target
Consensus Narrative from 14 Analysts
US$266.19
Fair Value
16.7% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 01:05
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Align Technology, Inc. is covered by 51 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research
Charley JonesBarrington Research Associates, Inc.